News | August 13, 2021
Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
Demand normalisation post the second wave contributed to the steady growth
Income declines marginally
It plays a pivotal role in monitoring pharmaceutical pricing
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
The company has strong product launches both in India and overseas
Subscribe To Our Newsletter & Stay Updated
